Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more
Corvus Pharmaceuticals Inc (CRVS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.133x
Based on the latest financial reports, Corvus Pharmaceuticals Inc (CRVS) has a cash flow conversion efficiency ratio of -0.133x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.57 Million) by net assets ($71.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Corvus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Corvus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Corvus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corvus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanobiotix
NASDAQ:NBTX
|
0.253x |
|
DEVELIA S.A. INH. ZY 1
F:94L
|
N/A |
|
GRUPO ELEKTRA (GE7C.SG)
STU:GE7C
|
0.204x |
|
Ganzhou Tengyuan Cobalt New Material Co. Ltd.
SHE:301219
|
N/A |
|
Trupanion Inc
NASDAQ:TRUP
|
0.076x |
|
Khang Dien House Trading and Investment JSC
VN:KDH
|
0.006x |
|
The First Bancshares, Inc.
NASDAQ:FBMS
|
0.018x |
|
Old Second Bancorp Inc
NASDAQ:OSBC
|
0.049x |
Annual Cash Flow Conversion Efficiency for Corvus Pharmaceuticals Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Corvus Pharmaceuticals Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $32.57 Million | $-25.42 Million | -0.781x | -26.17% |
| 2023-12-31 | $38.68 Million | $-23.93 Million | -0.619x | -28.48% |
| 2022-12-31 | $56.12 Million | $-27.02 Million | -0.482x | -27.44% |
| 2021-12-31 | $97.16 Million | $-36.72 Million | -0.378x | +21.61% |
| 2020-12-31 | $72.15 Million | $-34.78 Million | -0.482x | +8.15% |
| 2019-12-31 | $71.11 Million | $-37.32 Million | -0.525x | -41.28% |
| 2018-12-31 | $110.34 Million | $-40.99 Million | -0.371x | +31.80% |
| 2017-12-31 | $84.83 Million | $-46.21 Million | -0.545x | -159.68% |
| 2016-12-31 | $132.80 Million | $-27.86 Million | -0.210x | -157.59% |
| 2015-12-31 | $-31.10 Million | $-11.33 Million | 0.364x | -44.70% |
| 2014-12-31 | $-159.00K | $-104.73K | 0.659x | -- |